News about "obesity treatment "

Lilly's Zepbound Shows More Weight Loss Than Wegovy HD in Analysis

Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with greater weight loss than Wegovy HD (semaglutide 7.2 mg) in an indirect comparison.

Obesity Treatment | 01/10/2026 | By News Bureau

Roche Reports Positive Phase 2 Results for Enicepatide

Roche has announced positive phase 2 results for dual GLP-1/GIP receptor agonist enicepatide in people living with Type 2 Diabetes and overweight or obesity.

Obesity Treatment | 23/09/2026 | By News Bureau |  106

Ascletis Submits 2 IND Applications to the US FDA for the Treatment of Obesity

Ascletis has submitted two IND applications to the US FDA for once-monthly obesity therapies, including ASC36_35, a first-in-class triple-target candidate acting on amylin receptor, GLP-1R and GIPR.

Obesity Treatment | 06/07/2026 | By Akanki |  148

Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data

Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.

Obesity Treatment | 10/06/2026 | By News Bureau |  874

Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing

Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.

Obesity Treatment | 08/06/2026 | By News Bureau |  124

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US

UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.

Obesity Treatment | 04/06/2026 | By News Bureau |  140

Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003

Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.

Obesity Treatment | 18/05/2026 | By News Bureau |  374

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Obesity Treatment | 13/05/2026 | By News Bureau |  196

Neuland Laboratories Partners with LIR Life Sciences Corp to Advance Transdermal GLP-1 Obesity Therapy

Neuland Laboratories partnership with LIR Life Sciences Corp will focus on developing and manufacturing cell-penetrating peptides to support LIR Life’s patch-based GLP-1/GIP obesity treatment platform.

Obesity Treatment | 07/05/2026 | By News Bureau |  265

Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118

Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.

Obesity Treatment | 05/05/2026 | By News Bureau |  364